A phase 2B randomised trial of hyperbaric oxygen therapy for ulcerative colitis patients hospitalised for moderate to severe flares
| Autor: | Frank L. Ross, Renie Guilliod, Raymond K. Cross, David I. Fudman, Shannon Chang, Benjamin D. Levine, Laura E. Raffals, David Hudesman, Jay C. Buckey, M. Hassan Murad, Corey A. Siegel, Kinjal N. Sethuraman, Michael Winter, Charlotte Sadler, Gary N. Toups, Parambir S. Dulai, Ernest L. Chiu, Michael Chiorean, Tasneem Ahmed, James R. Holm |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male Moderate to severe medicine.medical_treatment Young Adult 03 medical and health sciences 0302 clinical medicine Hyperbaric oxygen medicine Humans Pharmacology (medical) 030212 general & internal medicine Dosing Adverse effect Colectomy Hyperbaric Oxygenation Hepatology business.industry Gastroenterology Middle Aged medicine.disease Ulcerative colitis Infliximab Hospitalization Anesthesia Colitis Ulcerative Female 030211 gastroenterology & hepatology Gastrointestinal Hemorrhage Intravenous steroids business medicine.drug |
| Zdroj: | Alimentary Pharmacology & Therapeutics. |
| ISSN: | 0269-2813 |
| Popis: | BACKGROUND: Hyperbaric oxygen has been reported to improve disease activity in hospitalised ulcerative colitis (UC) patients. AIM: To evaluate dosing strategies with hyperbaric oxygen for hospitalised UC patients. METHODS: We enrolled UC patients hospitalised for acute flares (Mayo score 6-12). Initially, all patients received 3 days of hyperbaric oxygen at 2.4 atmospheres (90 minutes with two air breaks) in addition to intravenous steroids. Day 3 responders (reduction of partial Mayo score ≥ 2 points and rectal bleeding score ≥ 1 point) were randomised to receive a total of 5 days vs 3 days of hyperbaric oxygen. RESULTS: We treated 20 patients with hyperbaric oxygen (75% prior biologic failure). Day 3 response was achieved in 55% (n = 11/20), with significant reductions in stool frequency, rectal bleeding and CRP (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text